• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most-Read Stories This Week—May 21

    Iterative Scopes Expands its Senior Leadership Team

    Viz.ai Raises $100 Million in Series D Funding

    FDA Clears Arterys' AI Mapping and Quantification Tools

    Prometheus Group Sued Over Reused Catheters and Rectal Sensors
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Injecting Neurostimulators into Blood Vessels (We Swear, It’s Not Sci-Fi)

    Understanding the Costs of Care in the OR

    Sick of Being Sick: Pandemic Fatigue Flares at AAOS

    Managing Critical Healthcare Supply Chains in Turbulent Times

    To Drive Value, Human Capital Leaders Turn to Outsourced Solutions
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Cirtec Medical

    Arthur G. Russell Co. Inc., The

    Trademark Plastics Inc.

    Xact Wire EDM Corp.

    BMP Medical
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    3D Printing in Dental Prosthodontics, Orthodontics, and Surgery

    What New Tech Can Improve Your Medical Manufacturing Plant?

    Why Medical Device Firms Must Navigate the Muddy Waters of ESG Requirements

    Medical Device Servicing vs. Remanufacturing

    Digital Marketplaces for Medical Equipment Come of Age
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Cirtec Medical

    Arthur G. Russell Co. Inc., The

    Trademark Plastics Inc.

    Xact Wire EDM Corp.

    BMP Medical
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Medical Device Funding: Any Signs of Life?

    ...

    Medical Device Funding: Any Signs of Life?
    Related CONTENT
    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    • Accu-Tube Appoints Matthew Haddle as CEO
    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    • CE Mark Granted to Predictive Software for Kidney Allograft Survival
    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Ben Dunn, Managing Director, Covington Associates05.01.17
    One of the most concerning aspects of the recent financial boom has been the lack of funding for medical device companies. While the implications of this shortage of capital have an immediate impact on anyone involved in the medical device industry, the shortage will eventually affect our entire society due to our dependence on medical devices that enhance the quality of life. As with most problems, the dearth in funding has been driven by various factors, rather than one single cause. 

    Taunted by the proclamations of record amounts of available investor capital and cash on company balance sheets, medical device companies of all sizes seeking investments have found it difficult to leverage such financing. With numerous reports about large amounts of available capital and investors’ struggle to put that money to work, the medical device entrepreneur must feel like he or she exists in a parallel universe, because none of the capital has trickled down. Whether it is a Series A or dreaded Series B round—which some refer to as the “valley of death”—it has been difficult to get an investor’s attention, let alone to convince them to part with their money. These obstacles expose more troubling and far-reaching issues within the medtech industry, namely, the amount of money available to companies and the reasons funding has become so difficult to obtain.

    Unlike in past years, there is a record amount of capital currently available for investment. According to Bain & Company, there was more than $1.4 trillion of committed but undeployed capital in private equity funds at the end of 2016, and that number doesn’t even include the large amounts of capital controlled by family offices or government investment arms.
    Moreover, the National Venture Capital Association reports that healthcare-focused venture capital funds raised over $12 billion of new capital in 2016. Clearly, there is a tremendous amount of dry powder for investment.

    So where is the money going?

    Certainly not into medical devices. The different investor classes—private equity, venture capital, and corporate investors—are funneling dollars into non-medtech sectors. Private equity firms have focused their investments on more mature businesses with stable cash flows and historical earnings (the opposite of a typical device company profile) while venture capital firms, which back early-stage companies, have invested heavily in non-medical technology organizations. The firms that have remained in healthcare have gravitated to biotechnology companies and ignored the medical device sector. Corporate investors, flush with cash and demonstrating a more risk averse strategy, have focused their efforts on less risky acquisitions rather than making investments in young companies. Rather than take the risk of investing in an early-stage business, OEMs are content to wait for a company to develop and ultimately pay more to acquire the business.

    Charts 1 and 2 (based on data compiled by Silicon Valley Bank) show the decline in medical device financing as a percentage of total venture investments. In 2016, of the approximately $75 billion of venture capital invested, just over 5 percent went to medical device companies. That figure represents a relative decrease of more than 50 percent compared with 2010, when over 11 percent of venture investments went toward medical devices. The impact of this relative decline is evident upon a closer examination of 2016, a year in which the aggregate amount of medical device investment dropped by 25 percent (from 2015) to $3.9 billion and the number of investments fell to a five-year low at 511.



    There are several reasons for this abscondence from medical devices. The most fundamental explanation involves the principal of risk versus return. Investors prefer financial prospects that give them the greatest chance of returns with the least amount of risk. When compared to other sectors, capitalists consider medical device investments as less attractive on the risk versus return scale. The environment for new medical devices has become much more challenging in recent years. U.S. Food and Drug Administration (FDA) approvals have been less predictable and more time-consuming. Consequently, the longer regulatory process increases time to market and reduces an investor’s time-based rate of return. Even after successfully navigating the FDA gauntlet, medical device companies are not out of the woods yet, as reimbursement has become much more uncertain and tedious. Investors used to be confident about product marketability upon regulatory approval, but that strategy is no longer viable. Regulatory approval is not enough to guarantee success—the device must now also demonstrate that it will be reimbursed and support value-based healthcare initiatives. 

    Not surprisingly, the liquidity path for medical device companies has become much more difficult as well. The initial public offering (IPO) window has been only open a crack (with a limited number of companies going public), forcing investors to rely on an M&A exit for their liquidity. And while medtech M&A remains very active, there have been some unfavorable changes in recent years affecting investments. Perhaps the most troubling change is the challenging regulatory environment, which has increased the amount of time it takes for an acquisition to occur. Previously, an acquisition would quickly follow regulatory approval; now companies wait to determine the type of market traction for a product (due to reimbursement concerns) before merging. Accordingly, the longer time frame makes an investment less valuable and increases its risk.

    Another factor significantly impacting medtech financing is the consolidation among large medical device OEMs. These unions are reducing the number of potential buyers of businesses, leaving investors with fewer exit options and lower values. Medical device exits for VC-backed companies hit a three-year low in 2016, with the industry experiencing only three IPOs and 13 M&A transactions, according to Silicon Valley Bank. Exits for device companies are taking longer and occurring increasingly in later stages. Over the past three years, two-thirds of the companies with meaningful exits have been commercial stage while only 18 percent have been pre-approval stage, thereby increasing the average time to exit for medical device companies to more than eight years in 2016.

    The industry’s financial struggles become even more troubling when compared with the glut of biotechnology investments. As medical device companies fight to attract funding, biotechnology firms have attracted record amounts of funding seemingly with ease. Since 2010, annual investments in biotechnology have more than doubled, from less than $4 billion annually to just under $9 billion. While this disparity certainly is frustrating to medtech entrepreneurs, there are some important factors that have made the biotechnology sector more appealing. First and foremost, biotechnology has produced several impressive exits for investors. It almost seems as if an early-stage biotechnology company is being acquired on a weekly basis. There has also been a steady stream of IPOs providing both liquidity for investors and new potential buyers for startups. Finally, biotechnology firms are striking deals earlier in their lifecycle. Investors don’t even wait for regulatory approval anymore—phase 2 clinical results are often sufficient for buyers. An evaluation of large biotechnology exits over the past two years shows that more than half of the major exits occurred in companies that were either in the pre-clinical stage or had just completed phase I trials. Considering most medical device exits occurred after eight years and well into commercialization, it is easy to understand the allure of the biotechnology sector. 

    A Light at the End of the Tunnel?
    Those of us who have lived through a number of business cycles know the investment pendulum will eventually swing back to medical devices. The long-term fundamentals of this market remain too strong and the global need too great for investors to ignore. Sooner or later, the sectors currently in favor will begin to overheat, burning stakeholders and forcing them to seek new investment areas. Intrepid and contrarian financiers who anticipate this shift will reap the greatest rewards, as they will realize there are great returns awaiting in the medical device space. The lack of recent funding has left fewer startups with which to compete, increasing companies’ chances of success. In time, healthcare investors will naturally start to look for alternatives to informatics and biotechnology ventures, and when they change their focus, they’ll find a new breed of medical device startups. In this class will be companies that have developed capital-efficient models through the effective use of outsourced partners. These companies will also be managed by executives who take nothing for granted and understand their products must provide better clinical efficacy as well as greater societal value.

    Cause for optimism can be found upon closer evaluation of medical device investments last year. Series A investments reached a 10-year high of 60 companies in 2016, nearly doubling from the previous year’s total. This shift could potentially indicate that institutional investors may be looking more closely at medical device companies and are planting more seeds. One can only hope that investors will continue to nurture these promising young companies and not let them wither on the vine. 


    Ben Dunn is a managing director with Boston, Mass.-based Covington Associates. For more than 20 years, he has advised medical technology companies in the areas of mergers, acquisitions, investments, and strategic partnerships. Having advised clients on more than 100 transactions, Dunn has represented both private and public companies on both the buy and sell side. He is a frequent speaker at healthcare conferences and the author of numerous articles, including the whitepaper, “Medical Device Outsourcing Industry: Emerging Trends and Opportunities.” 
    Related Searches
    • medical technology
    • series a
    • healthcare
    • regulatory
    Suggested For You
    Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    Accu-Tube Appoints Matthew Haddle as CEO Accu-Tube Appoints Matthew Haddle as CEO
    Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    CE Mark Granted to Predictive Software for Kidney Allograft Survival CE Mark Granted to Predictive Software for Kidney Allograft Survival
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Precision Coating Merges with N2 Biomedical Precision Coating Merges with N2 Biomedical
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Indago Announces $10 Million Financing Close and Name Change Indago Announces $10 Million Financing Close and Name Change
    Molli Surgical Molli Surgical's Breast Tumor Marker
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    RapidPulse Closes $15 Million Series A Financing RapidPulse Closes $15 Million Series A Financing
    Midwest Products & Engineering Acquires MindFlow Design Midwest Products & Engineering Acquires MindFlow Design
    Vicarious Surgical Opens New Corporate Headquarters in Massachusetts Vicarious Surgical Opens New Corporate Headquarters in Massachusetts
    Luis J. Malavé Joins Integrity Applications Board Luis J. Malavé Joins Integrity Applications Board
    Stryker Buys Gauss Surgical Stryker Buys Gauss Surgical

    Related Content

    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Neela Paykel is serving as general counsel and Tom Teisseyre assumes the chief product officer position.
      Business Wire 09.22.21

    • Tubing & Extrusion
      Accu-Tube Appoints Matthew Haddle as CEO

      Accu-Tube Appoints Matthew Haddle as CEO

      Haddle has a track record of leading organizations through strategic expansions across the medical device, aerospace, and industrial sectors.
      Accu-Tube 09.22.21

    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      The two deals will strengthen Heraeus' healthcare and medtech portfolio.
      Heraeus 09.22.21


    • CE Mark Granted to Predictive Software for Kidney Allograft Survival

      CE Mark Granted to Predictive Software for Kidney Allograft Survival

      Algorithm gives the probability the graft will still be functional at three, five, and seven years after evaluation by a healthcare professional.
      Cibiltech 09.21.21

    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Sleeve based on a medical technique called Direct Wire Pacing, which was invented by the company’s founder.
      Electroducer 09.21.21


      Trending
      • 5 Ways Plastics Revolutionized The Healthcare Industry | Medical Product Outsourcing
      • Smart LED Contact Lens Diagnoses Diabetes & Treats Retinopathy | Medical Product Outsourcing
      • FDA Clears Innovia Medical's Sterizone VP4 Sterilization Process | Medical Product Outsourcing
      • Medtronic's Onyx Frontier Drug-Eluting Stent Earns FDA Nod | Medical Product Outsourcing
      • Medtronic's Resolute Onyx Drug-Eluting Stent Shows Success For Left Main PCI | Medical Product Outsourcing
      Breaking News
      • MPO's Most-Read Stories This Week—May 21
      • Iterative Scopes Expands its Senior Leadership Team
      • Viz.ai Raises $100 Million in Series D Funding
      • FDA Clears Arterys' AI Mapping and Quantification Tools
      • Prometheus Group Sued Over Reused Catheters and Rectal Sensors
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Cybersecurity Challenges Leave Medical Device Makers Insecure
      • Contract Design for Medtech
      • Diabetes Medical Device Technology Update
      • Medtech Full-Service Outsourcing Q&A 2022

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Five PPG Facilities in Ohio Recognized for Sustainability, Health, Safety Practices
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 21
      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      ÄZ Craft Luxury Haircare Products Support All Hairstyles
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nazdar celebrates 100th anniversary with refreshed brand identity
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      'Right' Hygiene Conference to be Held in June
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most Read Stories This Week—May 21
      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login